Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $19.50.

A number of analysts have commented on ENTA shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, June 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ ENTA opened at $13.60 on Monday. The firm has a market cap of $396.03 million, a price-to-earnings ratio of -5.64 and a beta of 0.98. The company’s 50-day simple moving average is $13.59 and its 200-day simple moving average is $13.48. Enanta Pharmaceuticals has a 52-week low of $7.05 and a 52-week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The firm had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. Equities research analysts anticipate that Enanta Pharmaceuticals will post -2.36 EPS for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Meeder Asset Management Inc. purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $32,000. Seven Fleet Capital Management LP acquired a new position in Enanta Pharmaceuticals in the 4th quarter valued at about $36,000. Legal & General Group Plc purchased a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at approximately $41,000. Strs Ohio acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $50,000. Finally, Clearstead Trust LLC purchased a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $74,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.